PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.68M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
2541.03%
Net income growth 1.25-1.5x VET's 2241.68%. Bruce Berkowitz would verify whether cost discipline or revenue gains drive the outperformance.
-0.29%
Negative yoy D&A while VET is 4.86%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
2283.33%
Well above VET's 698.24% if it’s a large positive yoy. Michael Burry would see a bigger future tax burden vs. competitor’s approach.
-624.00%
Negative yoy SBC while VET is 30.05%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
-85.30%
Both reduce yoy usage, with VET at -169.65%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
125.00%
AR growth of 125.00% while VET is zero at 0.00%. Bruce Berkowitz would see a mild difference in credit approach that could matter for cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-85.67%
Both reduce yoy usage, with VET at -169.65%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
-478.95%
Both negative yoy, with VET at -448.69%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
-36.84%
Both yoy CFO lines are negative, with VET at -42.16%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
33.27%
CapEx growth well above VET's 61.08%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
4388.89%
Acquisition spending well above VET's 116.17%. Michael Burry would suspect heavier integration risk or short-term free cash flow drain vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1500.00%
We reduce yoy other investing while VET is 470.46%. Joel Greenblatt sees a near-term cash advantage unless competitor’s intangible or side bets produce strong returns.
86.02%
Investing outflow well above VET's 74.10%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
4.35%
Debt repayment similar to VET's 4.34%. Walter Schloss sees parallel liability management or similar free cash flow availability.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Buyback growth of 100.00% while VET is zero at 0.00%. Bruce Berkowitz sees a modest per-share advantage that might accumulate if the stock is below intrinsic value.